FTC settles with AbbVie, ending Actavis
The Federal Trade Commission wrapped up a watershed pay-for-delay lawsuit on Thursday, settling its claims that AbbVie had illegally paid off generic rivals to keep them from competing in a market for testosterone medication.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10